Acadia Pharmaceuticals Inc (ACAD) stock
ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 17/3041% below fair value
$18.75+0.61 (+3.36%)
Close on Nov 13, 2026Market cap $3.23BP/E 8.9Yield –
Acadia Pharmaceuticals EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Acadia Pharmaceuticals's EV/EBITDA was 25.5× on Nov 11, 2026, against 14.1× a year earlier. Over the last 3 years it ranged from 1.3× to 98.6×, with a median of 14.1×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 25.5× | +10.3 |
| 2025 | Dec 31, 2025 | 15.2× | −6.9 |
| 2024 | Dec 31, 2024 | 22.2× | +18.4 |
| 2012 | Jan 31, 2012 | 3.8× | +2.0 |
| 2011 | Dec 30, 2011 | 1.8× | – |
See a number that looks wrong?